Clinical Trial

A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in Adult Participants With Relapsed/Refractory CD19-positive B-cell Malignant Hematological Tumors

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This study is a prospective single-arm open-label clinical trial, including dose escalation and expansion phase, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in relapsed/refractory CD19 positive adult B-cell non Hodgkin lymphoma (B-NHL) and B-acute lymphoblastic leukemia (B-ALL) patients. A total of 34 subjects will be enrolled in this study.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-17.
Trial Details
NCT Number NCT07131254
Lead Sponsor Grit Biotechnology
Collaborators: Ganzhou City People's Hospital
Conditions Hematological Malignancy (Leukemia- Lymphoma)
Enrollment 34 participants
Start Date 2025-03-10
Primary Completion 2027-12-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-30